Stingless Bee Honey augmentation in Major Depressive Disorders. A Randomized Clinical Trial
Phase 2
- Conditions
- Oxidative StressMajor Depressive DisorderMemory And Learning TestMajor depressive disorderBrain Derived Neurotrophic Factor
- Registration Number
- TCTR20240621001
- Lead Sponsor
- /A
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Pending (Not yet recruiting)
- Sex
- All
- Target Recruitment
- 45
Inclusion Criteria
Adults with ages 18 to 65 with Major Depressive Disorder
Scores of Beck Depression Inventory Malay version equal or more than 11
Exclusion Criteria
Women in pregnancy or breast-feeding.
Patients who with honey allergy or stingless bee honey allergy.
Currently taking honey not limited to stingless bee honey or taken honey not limited to stingless bee honey in the past one month.
Patients with Major Depressive Disorder comorbidity either with generalized anxiety disorder, panic disorder, social anxiety disorder, bipolar disorder, substance-use disorder, suicidal ideation or attempt, dementia, Alzheimer disease, diabetic, hypertension, chronic kidney disease
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Depressive symptoms Before intervention, at week 4 during the intervention, at week 8 of the intervention Beck Depression Inventory Malay-version
- Secondary Outcome Measures
Name Time Method Oxidative stress Before intervention, at week 4 during the intervention, at week 8 of the intervention Serum malondialdehyde concentrations in blood,Brain derived neurotrophic factors, BDNF Before intervention, at week 4 during the intervention, at week 8 of the intervention Serum BDNF concentrations of blood,Verbal learning and memory Before intervention, at week 4 during the intervention, at week 8 of the intervention Malay version of auditory verbal learning test